Linked Life Data

7961585

Source:http://linkedlifedata.com/resource/pubmed/id/7961585

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1994-11-28
pubmed:abstractText
The advent of clozapine has marked a major advance in the treatment of schizophrenia because of its low incidence of extrapyramidal side effects and superior efficacy. Because of a relatively high incidence of agranulocytosis, approved indications for use are limited to treatment-refractory or neuroleptic-intolerant patients with schizophrenia. However, an emerging body of literature suggests that clozapine may be preferable to typical neuroleptics for treating psychosis in certain neurologic disorders. In addition, clozapine may have a place in the treatment of movement disorders that are caused by or are a result of the pharmacologic treatment of some neurologic illnesses. In general, clozapine doses used in these settings are lower than that for treating psychosis in schizophrenia. This article reviews the experience with clozapine in selected neurologic disorders.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0160-6689
pubmed:author
pubmed:issnType
Print
pubmed:volume
55 Suppl B
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
98-101
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
The use of clozapine in neurologic disorders.
pubmed:affiliation
Hillside Hospital-Psychiatry Research, Glen Oaks, N.Y.
pubmed:publicationType
Journal Article, Review